Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study

Joshua Osowicki, Kristy I. Azzopardi, Ciara Baker, Claire S. Waddington, Manisha Pandey, Tibor Schuster, Anneke Grobler, Allen C. Cheng, Andrew J. Pollard, James S. McCarthy, Michael F. Good, Mark J. Walker, James B. Dale, Michael R. Batzloff, Jonathan R. Carapetis, Pierre R. Smeesters, Andrew C. Steer

Research output: Contribution to journalArticle

Abstract

Group A Streptococcus (GAS) is a highly-adapted and human-restricted pathogen responsible for a high global burden of disease across a diverse clinical spectrum. Vaccine development has been impeded by scientific, regulatory, and commercial obstacles. Human infection studies (HIS) are increasingly contributing to drug, diagnostics, and vaccine development, reducing uncertainty at early stages, especially for pathogens with animal models that incompletely reproduce key elements of human disease. We review the small number of historical GAS HIS and present the study protocol for a dose-ranging inpatient study in healthy adults. The primary objective of the study is to establish a new GAS pharyngitis HIS with an attack rate of at least 60% as a safe and reliable platform for vaccine evaluation and pathogenesis research. According to an adaptive dose-ranging study design, emm75 GAS doses manufactured in keeping with principles of Good Manufacturing Practice will be directly applied by swab to the pharynx of carefully screened healthy adult volunteers at low risk of severe complicated GAS disease. Participants will remain as closely monitored inpatients for up to six days, observed for development of the primary outcome of acute symptomatic pharyngitis, as defined by clinical and microbiological criteria. All participants will be treated with antibiotics and followed as outpatients for six months. An intensive sampling schedule will facilitate extensive studies of host and organism dynamics during experimental pharyngitis. Ethics approval has been obtained and the study has been registered at ClinicalTrials.gov (NCT03361163).

Original languageEnglish
Pages (from-to)3485-3494
Number of pages10
JournalVaccine
Volume37
Issue number26
DOIs
Publication statusPublished - 6 Jun 2019

Fingerprint

Streptococcus pyogenes
Pharyngitis
Streptococcus
Vaccination
vaccination
Infection
infection
Vaccines
vaccine development
Inpatients
dosage
microbiological criteria
good manufacturing practices
burden of disease
pathogens
pharynx
ethics
Pharynx
human diseases
Ethics

Cite this

Osowicki, Joshua ; Azzopardi, Kristy I. ; Baker, Ciara ; Waddington, Claire S. ; Pandey, Manisha ; Schuster, Tibor ; Grobler, Anneke ; Cheng, Allen C. ; Pollard, Andrew J. ; McCarthy, James S. ; Good, Michael F. ; Walker, Mark J. ; Dale, James B. ; Batzloff, Michael R. ; Carapetis, Jonathan R. ; Smeesters, Pierre R. ; Steer, Andrew C. / Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS) : Establishing a group A Streptococcus pharyngitis human infection study. In: Vaccine. 2019 ; Vol. 37, No. 26. pp. 3485-3494.
@article{35f5627d36a14a0fa1767c97051ec986,
title = "Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study",
abstract = "Group A Streptococcus (GAS) is a highly-adapted and human-restricted pathogen responsible for a high global burden of disease across a diverse clinical spectrum. Vaccine development has been impeded by scientific, regulatory, and commercial obstacles. Human infection studies (HIS) are increasingly contributing to drug, diagnostics, and vaccine development, reducing uncertainty at early stages, especially for pathogens with animal models that incompletely reproduce key elements of human disease. We review the small number of historical GAS HIS and present the study protocol for a dose-ranging inpatient study in healthy adults. The primary objective of the study is to establish a new GAS pharyngitis HIS with an attack rate of at least 60{\%} as a safe and reliable platform for vaccine evaluation and pathogenesis research. According to an adaptive dose-ranging study design, emm75 GAS doses manufactured in keeping with principles of Good Manufacturing Practice will be directly applied by swab to the pharynx of carefully screened healthy adult volunteers at low risk of severe complicated GAS disease. Participants will remain as closely monitored inpatients for up to six days, observed for development of the primary outcome of acute symptomatic pharyngitis, as defined by clinical and microbiological criteria. All participants will be treated with antibiotics and followed as outpatients for six months. An intensive sampling schedule will facilitate extensive studies of host and organism dynamics during experimental pharyngitis. Ethics approval has been obtained and the study has been registered at ClinicalTrials.gov (NCT03361163).",
keywords = "Controlled human infection, Group A Streptococcus, Human challenge, Human infection studies, Streptococcus pyogenes, Vaccine development",
author = "Joshua Osowicki and Azzopardi, {Kristy I.} and Ciara Baker and Waddington, {Claire S.} and Manisha Pandey and Tibor Schuster and Anneke Grobler and Cheng, {Allen C.} and Pollard, {Andrew J.} and McCarthy, {James S.} and Good, {Michael F.} and Walker, {Mark J.} and Dale, {James B.} and Batzloff, {Michael R.} and Carapetis, {Jonathan R.} and Smeesters, {Pierre R.} and Steer, {Andrew C.}",
year = "2019",
month = "6",
day = "6",
doi = "10.1016/j.vaccine.2019.03.059",
language = "English",
volume = "37",
pages = "3485--3494",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "26",

}

Osowicki, J, Azzopardi, KI, Baker, C, Waddington, CS, Pandey, M, Schuster, T, Grobler, A, Cheng, AC, Pollard, AJ, McCarthy, JS, Good, MF, Walker, MJ, Dale, JB, Batzloff, MR, Carapetis, JR, Smeesters, PR & Steer, AC 2019, 'Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study' Vaccine, vol. 37, no. 26, pp. 3485-3494. https://doi.org/10.1016/j.vaccine.2019.03.059

Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS) : Establishing a group A Streptococcus pharyngitis human infection study. / Osowicki, Joshua; Azzopardi, Kristy I.; Baker, Ciara; Waddington, Claire S.; Pandey, Manisha; Schuster, Tibor; Grobler, Anneke; Cheng, Allen C.; Pollard, Andrew J.; McCarthy, James S.; Good, Michael F.; Walker, Mark J.; Dale, James B.; Batzloff, Michael R.; Carapetis, Jonathan R.; Smeesters, Pierre R.; Steer, Andrew C.

In: Vaccine, Vol. 37, No. 26, 06.06.2019, p. 3485-3494.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS)

T2 - Establishing a group A Streptococcus pharyngitis human infection study

AU - Osowicki, Joshua

AU - Azzopardi, Kristy I.

AU - Baker, Ciara

AU - Waddington, Claire S.

AU - Pandey, Manisha

AU - Schuster, Tibor

AU - Grobler, Anneke

AU - Cheng, Allen C.

AU - Pollard, Andrew J.

AU - McCarthy, James S.

AU - Good, Michael F.

AU - Walker, Mark J.

AU - Dale, James B.

AU - Batzloff, Michael R.

AU - Carapetis, Jonathan R.

AU - Smeesters, Pierre R.

AU - Steer, Andrew C.

PY - 2019/6/6

Y1 - 2019/6/6

N2 - Group A Streptococcus (GAS) is a highly-adapted and human-restricted pathogen responsible for a high global burden of disease across a diverse clinical spectrum. Vaccine development has been impeded by scientific, regulatory, and commercial obstacles. Human infection studies (HIS) are increasingly contributing to drug, diagnostics, and vaccine development, reducing uncertainty at early stages, especially for pathogens with animal models that incompletely reproduce key elements of human disease. We review the small number of historical GAS HIS and present the study protocol for a dose-ranging inpatient study in healthy adults. The primary objective of the study is to establish a new GAS pharyngitis HIS with an attack rate of at least 60% as a safe and reliable platform for vaccine evaluation and pathogenesis research. According to an adaptive dose-ranging study design, emm75 GAS doses manufactured in keeping with principles of Good Manufacturing Practice will be directly applied by swab to the pharynx of carefully screened healthy adult volunteers at low risk of severe complicated GAS disease. Participants will remain as closely monitored inpatients for up to six days, observed for development of the primary outcome of acute symptomatic pharyngitis, as defined by clinical and microbiological criteria. All participants will be treated with antibiotics and followed as outpatients for six months. An intensive sampling schedule will facilitate extensive studies of host and organism dynamics during experimental pharyngitis. Ethics approval has been obtained and the study has been registered at ClinicalTrials.gov (NCT03361163).

AB - Group A Streptococcus (GAS) is a highly-adapted and human-restricted pathogen responsible for a high global burden of disease across a diverse clinical spectrum. Vaccine development has been impeded by scientific, regulatory, and commercial obstacles. Human infection studies (HIS) are increasingly contributing to drug, diagnostics, and vaccine development, reducing uncertainty at early stages, especially for pathogens with animal models that incompletely reproduce key elements of human disease. We review the small number of historical GAS HIS and present the study protocol for a dose-ranging inpatient study in healthy adults. The primary objective of the study is to establish a new GAS pharyngitis HIS with an attack rate of at least 60% as a safe and reliable platform for vaccine evaluation and pathogenesis research. According to an adaptive dose-ranging study design, emm75 GAS doses manufactured in keeping with principles of Good Manufacturing Practice will be directly applied by swab to the pharynx of carefully screened healthy adult volunteers at low risk of severe complicated GAS disease. Participants will remain as closely monitored inpatients for up to six days, observed for development of the primary outcome of acute symptomatic pharyngitis, as defined by clinical and microbiological criteria. All participants will be treated with antibiotics and followed as outpatients for six months. An intensive sampling schedule will facilitate extensive studies of host and organism dynamics during experimental pharyngitis. Ethics approval has been obtained and the study has been registered at ClinicalTrials.gov (NCT03361163).

KW - Controlled human infection

KW - Group A Streptococcus

KW - Human challenge

KW - Human infection studies

KW - Streptococcus pyogenes

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=85065551948&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.03.059

DO - 10.1016/j.vaccine.2019.03.059

M3 - Article

VL - 37

SP - 3485

EP - 3494

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -